skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

About William


43+ years of experience

William is an Executive Editor at Informa Pharma Intelligence with primary responsibility for biopharma industry-related coverage for its flagship feature-oriented online and monthly print publication, In Vivo. Principal areas of focus include global commercial strategy; C-suite issues and operations; market access; reputation; regulation and policy.
William is responsible for editorial content and serves as a thought leader in contacts between In Vivo and a wide variety of external organizations he has been involved with over the course of his career. Prior to joining In Vivo, he was Editor-in-Chief of Pharmaceutical Executive magazine, where he was recognized by the business media press for excellence in editorial commentary.  He also served in industry as a Director at Pfizer Inc., managing the company's public policy issue development and positioning outside the US and coordinating various external leadership activities for the CEO.  William began his career as a business analyst for the Economist Intelligence Unit of the UK Economist Group. 

Analyst Articles

Articles by William

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

    How To Negotiate With Public Payers: Five Lessons - And A Few Cautions - From The UK's New Pact On Drug Price And Access

    By William Looney 27 Nov 2020

    In today’s globalized market for medicines, national rules on pricing and access are abundantly shared and more transparent than opaque. In Vivo speaks to the UK branded industry’s negotiator for the latest five-year joint pricing pact with the government, Richard Torbett, who outlines, among other topics, five widely applicable precedents from the talks that can work in “getting to yes” – despite the fractious budgetary climate for health care evident in all major country markets. 

    Topic Brexit Policy & Regulation

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

    ESG In 2020: Not A Tick-Box Exercise But A Strategic Opportunity

    By William Looney 27 Nov 2020


    The idea that public corporations have obligations that extend beyond the fiduciary responsibility to shareholders will be the dominant measure of responsible business behavior in the coming decade. Uncertainty about the extent of these commitments – commonly referenced as the environmental, social and governance (ESG) agenda – has produced equally variable responses from companies in the health care business.

    Topic Financing Strategy

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

    Bayer US Pharmaceuticals' Sebastian Guth: Designs On A New Decade

    By William Looney 27 Nov 2020


    Bayer’s ambitious campaign to reposition itself as a global leader in two complementary fields – health and nutrition – will face its toughest test in the US, with its highly litigious approach to product liability and a tendency to target pharmaceuticals as the source of the health system’s affordability and access problems.

    Topic Business Strategies Leadership

  • In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

    How Proximity Creates Partnerships

    By William Looney 08 Nov 2019


    Former Amgen R&D lead Sean Harper talks exclusively to In Vivo about his new role as a venture capitalist, joining veteran industry investor Beth Seidenberg as co-founder of Los Angeles-based Westlake Village BioPartners.

    Topic Business Strategies Deals